» Articles » PMID: 35011410

Evaluation of Virtual Screening Strategies for the Identification of γ-Secretase Inhibitors and Modulators

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Jan 11
PMID 35011410
Authors
Affiliations
Soon will be listed here.
Abstract

γ-Secretase is an intramembrane aspartyl protease that is important in regulating normal cell physiology via cleavage of over 100 transmembrane proteins, including Amyloid Precursor Protein (APP) and Notch family receptors. However, aberrant proteolysis of substrates has implications in the progression of disease pathologies, including Alzheimer's disease (AD), cancers, and skin disorders. While several γ-secretase inhibitors have been identified, there has been toxicity observed in clinical trials associated with non-selective enzyme inhibition. To address this, γ-secretase modulators have been identified and pursued as more selective agents. Recent structural evidence has provided an insight into how γ-secretase inhibitors and modulators are recognized by γ-secretase, providing a platform for rational drug design targeting this protease. In this study, docking- and pharmacophore-based screening approaches were evaluated for their ability to identify, from libraries of known inhibitors and modulators with decoys with similar physicochemical properties, γ-secretase inhibitors and modulators. Using these libraries, we defined strategies for identifying both γ-secretase inhibitors and modulators incorporating an initial pharmacophore-based screen followed by a docking-based screen, with each strategy employing distinct γ-secretase structures. Furthermore, known γ-secretase inhibitors and modulators were able to be identified from an external set of bioactive molecules following application of the derived screening strategies. The approaches described herein will inform the discovery of novel small molecules targeting γ-secretase.

Citing Articles

ADME profiling, molecular docking, DFT, and MEP analysis reveal cissamaline, cissamanine, and cissamdine from L.f. as potential anti-Alzheimer's agents.

Alhawarri M, Al-Thiabat M, Dubey A, Tufail A, Fouad D, Alrimawi B RSC Adv. 2024; 14(14):9878-9891.

PMID: 38528929 PMC: 10961956. DOI: 10.1039/d4ra01070a.


New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases.

De Strooper B, Karran E EMBO J. 2024; 43(6):887-903.

PMID: 38396302 PMC: 10943082. DOI: 10.1038/s44318-024-00057-w.


Microorganism-Derived Molecules as Enzyme Inhibitors to Target Alzheimer's Diseases Pathways.

Nguyen T, Wang S, Nguyen V Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111337 PMC: 10146315. DOI: 10.3390/ph16040580.

References
1.
Mancarella S, Serino G, Dituri F, Cigliano A, Ribback S, Wang J . Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell Death Differ. 2020; 27(8):2330-2343. PMC: 7370218. DOI: 10.1038/s41418-020-0505-4. View

2.
Yang Z, Li J, Xiao L, Mou L, Cai Y, Huang H . [(3) H]-L685,458 binding sites are abundant in multiple peripheral organs in rats: implications for safety assessment of putative γ-secretase targeting drugs. Basic Clin Pharmacol Toxicol. 2014; 115(6):518-26. DOI: 10.1111/bcpt.12271. View

3.
Araya E, Rodriguez A, Rubio J, Spada A, Joglar J, Llebaria A . Synthesis and evaluation of diverse analogs of amygdalin as potential peptidomimetics of peptide T. Bioorg Med Chem Lett. 2005; 15(5):1493-6. DOI: 10.1016/j.bmcl.2004.12.071. View

4.
Doherty A, Kaltenbronn J, HUDSPETH J, Repine J, Roark W, Sircar I . New inhibitors of human renin that contain novel replacements at the P2 site. J Med Chem. 1991; 34(4):1258-71. DOI: 10.1021/jm00108a004. View

5.
Williamson R, Hakenbeck R, Tomasz A . In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980; 18(4):629-37. PMC: 284061. DOI: 10.1128/AAC.18.4.629. View